Ardelyx rises after new CFO appointment
** Shares of biopharmaceutical company Ardelyx ARDX.O up 1.93% to $5.03 ** Co appoints Sue Hohenleitner as chief financial officer, effective November 4 ** Hohenleitner most recently served as the vice president and CFO of Johnson & Johnson Innovative Medicine North America ** Justin Renz, the current CFO, will continue in his role through co's Q3 10-Q filing ** YTD, the stock has fallen ~1%, including session's moves (Reporting by Krisha Bhatt) ((Krisha.Bhatt@thomsonreuters.com;))
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million